Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Condition: Asthma
Interventions: Drug: 50 mcg salmeterol HFA MDI; Drug: placebo; Drug: 5 mcg tiotropium Respimat®; Drug: 2.5 mcg tiotropium Respimat®
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting – verified September 2010